Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
NTPC, a leading power giant in India, has unveiled its plans to set up a…
Tata Power Renewable Energy, a unit of Tata Power, has formed a partnership with the…
ICICI Bank and Times Internet have launched the ‘Times Black ICICI Bank Credit Card,’ a…
Reserve Bank of India (RBI) imposed penalties on IndusInd Bank and Manappuram Finance for failing…
UltraTech Cement, a flagship company of the Aditya Birla Group, has secured approval from the…
India faces a significant problem with road accidents, with certain states reporting higher numbers than…